Innate Pharma SA has reported positive outcomes from the Phase 2 TELLOMAK trial evaluating lacutamab for the treatment of mycosis fungoides, a type of cutaneous T-cell lymphoma. The study demonstrated that lacutamab, an anti-KIR3DL2 humanized cytotoxicity-inducing antibody, achieved promising efficacy and safety results in this patient population.
The TELLOMAK trial, an open-label, multi-cohort study, assessed the safety and efficacy of lacutamab in patients with advanced T-cell lymphomas. The mycosis fungoides cohort, which included patients who had received at least two prior systemic therapies, showed encouraging clinical benefit and a manageable safety profile for lacutamab.
These findings support the potential of lacutamab as a novel therapeutic option for patients with relapsed or refractory mycosis fungoides. Innate Pharma plans to further evaluate the clinical development of lacutamab and engage with regulatory authorities to discuss the future path forward for this promising immunotherapy candidate.
